Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Unresectable HER2-Negative Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: DRUG: Abemaciclib|DRUG: Anastrozole|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Diagnostic Imaging|DRUG: Exemestane|OTHER: Fludeoxyglucose F-18|DRUG: Fluorine F 18 Fluoro Furanyl Norprogesterone|DRUG: Fulvestrant|BIOLOGICAL: Gonadotropin-releasing Hormone Analog|DRUG: Letrozole|PROCEDURE: Positron Emission Tomography|DRUG: Tamoxifen|DRUG: Therapeutic Estradiol
Sponsor: University of Washington
Collaborators: Breast Cancer Research Foundation